- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07909226
Lactate/Albumin Ratio and Mortality in Respiratory Failure
The Prognostic Role of the Lactate/Albumin Ratio in Predicting 28-Day Mortality in Patients Admitted to the Intensive Care Unit With a Diagnosis of Respiratory Failure
This retrospective observational study aims to evaluate the association between the lactate-to-albumin ratio (LAR) measured at ICU admission and 28-day mortality in adult patients admitted to the intensive care unit with acute respiratory failure. The study will also compare the prognostic value of LAR with that of existing clinical and laboratory parameters.
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
Acute respiratory failure is a common cause of intensive care unit (ICU) admission and is associated with high short-term mortality. Early risk stratification is important for guiding treatment intensity and resource allocation. Serum lactate reflects tissue hypoperfusion and impaired oxygen utilization, whereas serum albumin is a marker of nutritional status, systemic inflammation, and capillary leak. The lactate-to-albumin ratio (LAR) combines these two readily available laboratory parameters and has been proposed as a prognostic marker in critically ill patients. However, its prognostic value in patients with acute respiratory failure has not been well established.
This is a single-center, retrospective observational cohort study conducted at Kocaeli City Hospital, including adult patients (≥18 years) admitted to the ICU with acute respiratory failure between April 2023 and June 2026. Data will be obtained from the hospital information system and ICU records.
The primary objective is to evaluate the association between LAR at ICU admission and 28-day all-cause mortality. The secondary objective is to compare the prognostic performance of LAR with that of serum lactate alone, serum albumin alone, and established severity scores (e.g., APACHE II, SOFA).
The following data will be collected: demographic characteristics, comorbidities, cause of respiratory failure, need for invasive mechanical ventilation, severity scores, laboratory parameters (including lactate and albumin measured at ICU admission), ICU and hospital length of stay, and 28-day survival status. LAR will be calculated as serum lactate (mmol/L) divided by serum albumin (g/dL).
Patients will be grouped as survivors and non-survivors at 28 days. The association between LAR and mortality will be assessed using logistic regression and/or Cox proportional hazards models adjusted for relevant confounders. Discriminative ability will be evaluated with receiver operating characteristic (ROC) curve analysis, and the optimal cut-off value will be determined. AUC values of LAR and the comparator parameters will be compared.
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Aytuğ Yıldız, MD
- Telefonnummer: +905445306369
- E-Mail: aytugyildiz9093@gmail.com
Studienorte
-
-
Kocaeli
-
İzmit, Kocaeli, Türkei (türkiye), 41100
- Rekrutierung
- Kocaeli City Hospital
-
Kontakt:
- Ahmet Yüksek, MD
- Telefonnummer: 05326580351
- E-Mail: mdayuksek@hotmail.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Adult patients (≥18 years) admitted for the first time to the intensive care unit of the Department of Anesthesiology and Reanimation, Kocaeli City Hospital, Turkey, with a diagnosis of acute respiratory failure between April 2023 and June 2026. Data will be retrospectively obtained from the hospital information system and patient records.
Beschreibung
Inclusion Criteria:
- Age 18 years or older
- First ICU admission with a diagnosis of acute respiratory failure between April 2023 and June 2026
Exclusion Criteria:
- Missing data in the hospital information system
- Known terminal-stage solid organ malignancy
- Laboratory data (lactate/albumin) obtained after albumin replacement
- ICU stay shorter than 24 hours
- Death within the first 24 hours of ICU admission
- Pregnancy
- Cardiopulmonary resuscitation within 24 hours before ICU admission
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: RETROSPECTIVE
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
ICU patients with acute respiratory failure
Adult (≥18 years) patients admitted to the ICU with acute respiratory failure between April 2023 and June 2026, in whom lactate and albumin were measured at ICU admission. LAR will be calculated and its association with 28-day mortality will be evaluated. |
In this observational cohort study, no experimental clinical intervention was administered. The primary exposure variable (prognostic marker/predictor) evaluated is the Lactate-to-Albumin Ratio (LAR), calculated from serum lactate level (mmol/L) divided by serum albumin level (g/dL) measured within the first 24 hours of intensive care unit admission. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Prognostic performance of LAR for 28-day mortality
Zeitfenster: 28 days after ICU admission
|
Discriminative ability of LAR at ICU admission for predicting 28-day mortality, assessed by the area under the receiver operating characteristic curve (AUC), with determination of the optimal cut-off value. |
28 days after ICU admission
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
7-day mortality
Zeitfenster: 7 days after ICU admission
|
Death from any cause within 7 days after ICU admission. |
7 days after ICU admission
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Comparison of LAR with serum lactate and serum albumin alone
Zeitfenster: 28 days after ICU admission
|
Comparison of the predictive performance (AUC) of LAR with that of lactate alone and albumin alone for 28-day mortality. |
28 days after ICU admission
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Ahmet Yüksek, MD, Kocaeli City Hospital
- Hauptermittler: Aytuğ Yıldız, MD, Kocaeli City Hospital
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Tong H, Zhou W, Wu L, Zhu Q. Response to: Interpreting the prognostic value of the lactate-to-albumin ratio in severe acute pancreatitis. Saudi J Gastroenterol. 2026 Oct 13. doi: 10.4103/sjg.sjg_392_26. Online ahead of print. No abstract available.
- C HP, Kumar PA. Lactate-albumin ratio as an early predictor of mortality in critically ill children: A prospective cohort study. Eur J Pediatr. 2026 Oct 16;185(11):854. doi: 10.1007/s00431-026-07525-x.
- Arslan Aksu E, Ozdemir L, Gegin S, Ozdemir B. Prognostic value of systemic inflammatory markers in patients with malignancy-associated pulmonary thromboembolism: A retrospective observational study. Medicine (Baltimore). 2026 Oct 16;105(42):e51137. doi: 10.1097/MD.0000000000051137.
- Mu Y, Tang H, Zeng Y, Wang Q, Huang T, Li W, Wu X, Pi S. LDAR shows more consistent prognostic performance than other albumin-derived indices for 28-day ICU mortality in critically ill patients with urosepsis: evidence from a dual-cohort retrospective study. Front Med (Lausanne). 2026 Oct 1;13:1915095. doi: 10.3389/fmed.2026.1915095. eCollection 2026.
- Li G, Zhang D, Yuan F, Li M, Wang Y, Zhou J, Fu Y. Association of the lactate dehydrogenase-to-albumin ratio with all-cause and non-relapse mortality in patients with aGVHD after allogeneic HSCT: a single-center retrospective cohort study. Front Immunol. 2026 Oct 9;17:1936503. doi: 10.3389/fimmu.2026.1936503. eCollection 2026.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2026-174
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
The study data may be shared upon an appropriate request and institutional approval. It is not publicly available.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .